Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities for personalized medicine. In this study, we aim to illustrate the implementation of NGS-based liquid biopsy in clinical practice for the detection of somatic alterations in selected genes. Our work is...
Main Authors: | Elisabetta Zulato, Valeria Tosello, Giorgia Nardo, Laura Bonanno, Paola Del Bianco, Stefano Indraccolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/8/1468 |
Similar Items
-
Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform
by: Irene Vanni, et al.
Published: (2015-12-01) -
Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity
by: Maxim Ivanov, et al.
Published: (2019-03-01) -
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
by: Martyna Filipska, et al.
Published: (2021-06-01) -
Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
by: Marta Sesé, et al.
Published: (2019-08-01) -
Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
by: Riziero Esposito Abate, et al.
Published: (2020-12-01)